Clinical Trial Update: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial of maintenance Fluzoparib in gBRCA/PALB2-mutated metastatic pancreatic cancer terminated after first-line platinum therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Fluzoparib (fluzoparib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Metastatic Pancreatic Cancer | Phase 3 | Status: TERMINATED